# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and lowers the price target fr...
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 pr...
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 pr...
Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achievedenGene plans to provide an update fro...
Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development toolsDesignation recognize...
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0...
JMP Securities analyst Silvan Tuerkcan reiterates enGene Holdings (NASDAQ:ENGN) with a Market Outperform and maintains $18 p...